Exempt life-saving drugs from 'any levies': Mazumdar-Shaw

Says levying any kind of duty on life saving drug does not resonate well with the healthcare mission

Image via Shutterstock
<a href="http://www.shutterstock.com/pic-141058420.html" target="_blank">Image</a> via Shutterstock
Press Trust of India New Delhi
Last Updated : Feb 08 2016 | 1:11 AM IST
Levying any kind of duty on life-saving drugs does not resonate well with India’s affordable health care mission, said Biocon Chairman and Managing Director Kiran Mazumdar-Shaw (pictured) on Sunday.

“We should, as a country, exempt life saving drugs from any kind of levies. Because after all you want affordable access,” Mazumdar-Shaw told NDTV.

Recently, the Central Board of Excise and Customs (CBEC) had issued a notification withdrawing exemption of levy of basic customs duty on as many as 74 drugs. The medicines on which customs duty will now be imposed include the ones used for treating kidney stones, cancer chemotherapy and radiotherapy, life-threatening heart rhythm disorders, diabetes, Parkinson’s disease, bone diseases and antibiotics to treat infections.

Besides, drugs used for bacterial infections, leukemia, anesthetic medication, human immunodeficiency virus (HIV) or hepatitis B virus cells, allergies, arthritis, lupus and ulcerative colitis might also see spurt in prices.

Apart from that, drugs used in blood dilating medicine would also attract customs duty.

However, experts believe the move seems to be in line with the government's objective to rationalise the duty exemptions.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Feb 08 2016 | 12:36 AM IST

Next Story